Search results for Receptor tyrosine-protein kinase erbB-2

PathScan^®Phospho-HER2/ErbB2 (Tyr1221/1222) Sandwich ELISA Kit#7148, Cell Signaling Technology (CST), 7148

PathScan^®Phospho-HER2/ErbB2 (Tyr1221/1222) Sandwich ELISA Kit detects endogenous levels of phospho-HER2/ErbB2 (Tyr1221/1222) protein. As shown in Figure 1, using this kit, a high level of phospho-HER2/ErbB2 (Tyr1221/1222) protein is detected in Calu-3 cells, and the levels are significantly reduced in Calu-3 cells treated with λ protein phosphastase. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.

PathScan^®RP Total HER2/ErbB2 Sandwich ELISA Kit#7310, Cell Signaling Technology (CST), 7310

PathScan^®RP Total HER2/ErbB2 Sandwich ELISA Kit #7310 detects endogenous levels of total HER2/ErbB2 protein in Calu-3 cells. This kit sensitivity is shown in Figure 1. This kit does not cross-react with other proteins of ErbB family (data not shown). This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.

Anti-Human CD340/ERBB2/HER2 Antibody (4D5V8), PerCP (HY286147), abinScience, HY286147

Anti-Human CD340/ERBB2/HER2 Antibody (4D5V8), FITC (HY286117), abinScience, HY286117

Anti-Human CD340/ERBB2/HER2/NEU Antibody (A21), APC (HY286337), abinScience, HY286337

Research Grade Anti-Human CD340/ERBB2/HER2/NEU (MEDI4276) (HY286566), abinScience, HY286566

Anti-Human CD340/ERBB2/HER2 Antibody (4D5V8), APC (HY286137), abinScience, HY286137

Research Grade Cinrebafusp alfa (HC336186), abinScience, HC336186

Ado-Trastuzumab Emtansine Biosimilar - Research Grade, ichor.bio, ICH4014

Detects human HER2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ado-trastuzumab emtansine.

Pertuzumab Biosimilar - Research Grade, ichor.bio, ICH4030

Detects human HER2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Pertuzumab.